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Abstract: Long-acting injectable (LAI) formulations of antipsychotics are valuable treatment alternatives for patients 
with psychotic disorders, and understanding their safe use is critical. Post-injection delirium/sedation syndrome (PDSS) 
has been reported following treatment with one atypical antipsychotic LAI. Clinical databases of risperidone LAI and 
paliperidone palmitate were explored to identify if cases of PDSS had been observed. 
No cases of PDSS were identified in 15 completed trials of 3,164 subjects (approximately 115,000 injections) or the 
postmarketing safety database of risperidone LAI. Only one case of PDSS was identified among 10 completed trials 
(3,817 subjects, 33,906 injections) of paliperidone palmitate—that case having been reported in a patient randomized to 
treatment with placebo. Examination of these prospective databases finds no evidence that risperidone LAI and 
paliperidone palmitate are associated with PDSS and suggest that findings seen with another antipsychotic LAI are not 
generalizable. 
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INTRODUCTION 
 Long-acting injectable (LAI) formulations of 
antipsychotic agents offer advantages to the use of orally 
administered agents in patients with schizophrenia who have 
difficulties with compliance and are at risk for relapse [1]. 
While these formulations are generally well-tolerated, a 
review by Citrome [2] and other reports [3-7] indicated a 
potential for patients to experience a constellation of 
neurologic symptoms following administration of one 
atypical antipsychotic LAI that are consistent with overdose 
and are referred to as post-injection delirium/sedation 
syndrome (PDSS). In a letter from the manufacturer [8], 
these events occur in <0.1% of injections and in 
approximately 2% of patients who received injections for up 
to 46 months. The time after injection to event ranges from 
soon after the injection to greater than 3 hours, with the risk 
being highest during the first hour [8]. According to the 
letter, the risk of an event is the same following each 
injection and, as so, cumulative (i.e., it increases with the 
number of injections) [8]. These analyses were performed to 
determine whether cases of PDSS or symptoms consistent 
with antipsychotic overdose have been reported for 
risperidone LAI and paliperidone palmitate. 
EVALUATION OF PDSS WITH RISPERIDONE LAI 
AND PALIPERIDONE PALMITATE 
  The clinical trial databases for 15 completed studies 
(3,164 subjects, 115,000 injections) and the postmarketing  
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safety database for risperidone LAI, and from 10 completed 
clinical trials (3,817 subjects; 33,906 injections; 1,704.8 
subject-years) of paliperidone palmitate were evaluated for 
reports of PDSS. A PDSS identification algorithm was 
created based upon literature descriptions of PDSS [5-8] 
methods and processes used in prior reports of antipsychotic 
LAI-related PDSS. The 4-part PDSS algorithm (Fig. 1) 
included the following steps: 
1)  Development of a summary list of sedation/somno-
lence events of interest (SSEs) from subjects who 
experienced at least 1 event coded to MedDRA 
preferred terms of sedation, somnolence, hyper-
somnia, lethargy, narcolepsy, or sudden onset of sleep 
at any time; 
2)  Creation of a subset listing of subjects who exper-
ienced at least 1 severe SSE within 1 day of receiving 
an injection; and who experienced at least 1 of the 
following MedDRA events within 1 day of the 
injection associated with the severe SSE: cataplexy, 
coma, consciousness fluctuating, depressed level of 
consciousness, loss of consciousness, sopor, stupor, 
unresponsive to stimuli, any of the preferred terms 
under the MedDRA high level group term (HLGT) 
seizures, any of the terms within the standardized 
MedDRA query (SMQ) of extrapyramidal syndrome, 
gait disturbance, gait deviation, parkinsonian gait, 
tachycardia, sinus tachycardia, hypotension, ortho-
static hypotension, diastolic hypotension, or any of 
the terms within the SMQ Torsades de Pointes; and 
finally; 
3)  Performance of a manual review of all subjects 
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limited to those who were hospitalized or required 
prolonged hospitalization to manage the severe 
sedation/somnolence event. 
PDSS FINDINGS WITH RISPERIDONE LAI AND 
PALIPERIDONE PALMITATE 
 Table  1 summarizes the incidences of treatment-emergent 
SSEs identified in steps 1 to 3 of the algorithm. Examination 
of the clinical trial and post-marketing risperidone databases 
revealed no cases of treatment-emergent SSEs that met the 
algorithm criteria for PDSS. Although 244 (8%) risperidone- 
and 8 (2%) placebo-treated subjects had at least 1 SSE, only 
1 case (risperidone-treated) occurred within 1 day of the 
injection and it was not associated with concurrent excessive 
SSE symptoms and therefore did not meet the criteria for a 
PDSS event. 
  One case meeting all of the algorithm requirements for 
PDSS was identified in the review of the clinical trial 
paliperidone palmitate databases. This case occurred in a 
patient enrolled in a double-blind clinical trial who had been 
randomized to placebo treatment. The patient was a 39-year-
old Asian female with a history of schizophrenia, mixed 
hyperlipidemia, obesity, and secondary parkinsonism. 
Within hours of her Study Day 1 administration of placebo, 
she experienced a generalized seizure followed by symptoms 
of drowsiness, urinary incontinence and post-ictal confusion 
(likely secondary to the seizure) and was hospitalized. 
  Upper 95% confidence limits for the probability of a 
PDSS event, given no events in 115,000 risperidone LAI 
injections and no events in 33,906 paliperidone palmitate 
injections are 0.003% and 0.01%, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). PDSS determination algorithm. 
Table 1.  Incidence of SSE (Any, Severe and Excessive) Identified in the Paliperidone Palmitate and Risperidone LAI Clinical Trial 
Databases 
 
Algorithm Step  Placebo  Paliperidone Palmitate  Risperidone LAI 
Step 1. Any Sedation/Somnolence Event (SSE)  Number of Subjects with 1 SSE/Total Subjects (%) 
Paliperidone palmitate studies  19/713 (3%)  95/3,817 (3%)  28/1,199 (2%) 
Risperidone LAI studies  8/323 (2%)  ---  244/3,164 (8%) 
Step 2. Severe SSE within 1 day of injection   Severe SSE Events/Total Injections 
Paliperidone palmitate studies  1/2,370  2/33,906  0/13,497 
Risperidone LAI studies  0/3,713  ---  1/115,000 
Step 3. Satisfied Step 2 and had an Excessive SSE within 1  
day of the same injection as in Step 2 
PDSS Events/Total Injections 
Paliperidone palmitate studies  1/2,370  0/33,906  0/13,497 
Risperidone LAI studies  0/3,713  ---  0/115,000 Long-Acting Intramuscular Formulations of Risperidone  Current Drug Safety, 2011, Vol. 6, No. 1    45 
SUMMARY 
  No reports or signals of PDSS were identified in subjects 
treated with either risperidone LAI or paliperidone palmitate. 
Given the sample sizes explored, there is 95% confidence 
that the true probability of a PDSS event is less than 0.003% 
following risperidone LAI injections and less than 0.01% 
following paliperidone palmitate injections. PDSS has been 
proposed to occur as a result of systemic exposure to an LAI 
with high blood/plasma solubility. Neither risperidone LAI 
or paliperidone palmitate have high water solubility. 
Risperidone LAI is an aqueous suspension wherein the 
active drug substance is encapsulated in a microsphere of 
polylactide-co-glycolide polymer. After injection, a small 
amount of risperidone (<1%) is released by diffusion within 
24 hours. The remaining drug is gradually released as the 
microsphere copolymer is hydrolyzed and result in a low and 
steady release of risperidone over a period of several weeks, 
with the majority being released during weeks 4 to 6 
following injection [9, 10]. Paliperidone palmitate dissolves 
slowly after intramuscular injection and is hydrolyzed to 
paliperidone, producing sustained therapeutic plasma 
concentrations with administration of two initiation doses 
(administered one week apart) followed by once-monthly 
maintenance doses [11]. 
  In summary, these results suggest that risperidone LAI 
and paliperidone palmitate do not have measurable risk for 
post-injection delirium/sedation syndrome. 
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